Troglitazone Reduces Cell Movement in Ovarian Cancer Cells
Author Information
Author(s): Yang Yuh-Cheng, Ho Tsung-Chuan, Chen Show-Li, Lai Huei-Yi, Wu Ju-Yun, Tsao Yeou-Ping
Primary Institution: Mackay Medicine, Nursing and Management College, Taipei, Taiwan
Hypothesis
Does troglitazone inhibit cell migration in human ovarian carcinoma cells?
Conclusion
Troglitazone effectively suppresses the migration of ovarian cancer cells by affecting focal adhesion and PTEN activity.
Supporting Evidence
- Troglitazone treatment reduced cell migration in a dose-dependent manner.
- At 20 μM, troglitazone decreased cell migration by 76% after 24 hours.
- Troglitazone inhibited the formation of focal adhesions and stress fibers.
Takeaway
Troglitazone is a medicine that can help stop cancer cells from moving around in the body, which is important for treating cancer.
Methodology
The study used wound-healing and transwell assays to evaluate cell migration after treating ES-2 ovarian carcinoma cells with troglitazone.
Participant Demographics
Human ovarian carcinoma cell line, ES-2.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website